Intravenous immunoglobulins in MS

International MS Journal

Volumn 12, Issue 1, 2005, Pages 4-10

  Stangel, Martin ^a   Gold, R ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Intravenous immunoglobulins; IVIG; Multiple sclerosis; Pregnancy; Relapses; Remyelination

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; BETA INTERFERON; CYTOKINE; IMMUNOGLOBULIN;

AUTOIMMUNE DISEASE; CELLULAR IMMUNITY; CLINICAL TRIAL; COMPLEMENT INHIBITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENDRITIC CELL; DISEASE COURSE; DRUG MECHANISM; HUMAN; HUMORAL IMMUNITY; IMMUNE SYSTEM; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; PROPHYLAXIS; RECURRENT DISEASE; RELAPSE; REMISSION; REMYELINIZATION; REVIEW; T LYMPHOCYTE;

EID: 20544451738     PISSN: 13528963     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Imbach P, Barandun S, d'Apuzzo V, Baumgartner C, Hirt A, Morell A et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981; i: 1228-1231.
2. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345: 747-755.
3. Stangel M, Toyka KV, Gold R. Mechanisms of high-dose intravenous immunoglobulins in demyelinating diseases. Arch Neurol 1999; 56: 661-663.
4. Rothfelder U, Neu I, Pelka R. Therapy of multiple sclerosis with immunoglobulin G. MMW Munch Med Wochenschr 1982; 124: 74-78 (in German).
5. Schuller E, Govaerts A. First results of immunotherapy with immunoglobulin G in multiple sclerosis patients. Eur Neurol 1983; 22: 205-212.
6. Soukop W, Tschabitscher H. Gamma globulin therapy in multiple sclerosis. Theoretical considerations and initial clinical experience with 7S immunoglobulins in MS therapy. Wien Med Wochenschr 1986; 136: 477-480 (in German).
7. Achiron A, Pros E, Gilad R, Ziv I, Mandel M, Gordon CR et al. Open controlled therapeutic trial of intravenous immune globulin in relapsing-remitting multiple sclerosis. Arch Neurol 1992; 49: 1233-1236.
8. Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group. Lancet 1997; 349: 589-593.
9. Achiron A, Gabbay U, Gilad R, Hassin-Baer S, Barak Y, Gornish M et al. Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology 1998; 50: 398-402.
10. Sorensen PS, Wanscher B, Jensen CV, Schreiber K, Blinkenberg M, Ravnborg M et al. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology 1998; 50: 1273-1281.
11. Teksam M, Tali T, Kocer B, Isik S. Qualitative and quantitative volumetric evaluation of the efficacy of intravenous immunoglobulin in multiple sclerosis: preliminary report. Neuroradiology 2000; 42: 885-889.
12. Lewanska M, Siger-Zajdel M, Selmaj K. No difference in efficacy of two different doses of intravenous immunoglobulins in MS: clinical and MRI assessment. Eur J Neurol 2002; 9: 565-572.
13. Sorensen PS, Fazekas F, Lee M. Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis. Eur J Neurol 2002; 9: 557-563.
14. Rieckmann P, Toyka KV, Bassetti C, Beer K, Beer S, Buettner U et al. Multiple Sclerosis Therapy Consensus Group. Escalating immunotherapy of multiple sclerosis - new aspects and practical application. J Neurol 2004; 251: 1329-1339.
15. Rieckmann P, Toyka KV. Escalating immunotherapy of multiple sclerosis. Austrian-German-Swiss Multiple Sclerosis Therapy Consensus Group [MSTCG]. Eur Neurol 1999; 42: 121-127.
16. Cook SD, Troiano R, Rohowsky-Kochan C, Jotkowitz A, Bielory L, Mehta PD et al. Intravenous gamma globulin in progressive MS. Acta Neurol Scand 1992; 86: 171-175.
17. Francis GS, Freedman MS, Antel JP. Failure of intravenous immunoglobulin to arrest progression of multiple sclerosis: a clinical and MRI based study. Mult Scler 1997; 3: 370-376.
18. Hommes OR, Sorensen PS, Fazekas F, Enrique MM, Koelmel HW, Fernandez O et al. Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial. Lancet 2004; 364: 1149-1156.
19. Poehlau D, Federlein J, Postert T, Sailer M, Bethke F, Kappos L et al. Intravenous immunoglobulin (IVIG] treatment for patients with primary or secondary progressive multiple sclerosis - outline of a double-blind randomized, placebo-controlled trial. Mult Scler 1997; 3: 149-152.
20. Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med 1998; 339: 285-291.
21. Achiron A, Rotstein Z, Noy S, Mashiach S, Dulitzky M, Achiron R. Intravenous immunoglobulin treatment in the prevention of childbirth-associated acute exacerbations in multiple sclerosis: a pilot study. J Neurol 1996; 243: 25-28.
22. Orvieto R, Achiron R, Rotstein Z, Noy S, Bar-Hava I, Achiron A. Pregnancy and multiple sclerosis: a 2-year experience. Eur J Obstet Gynecol Reprod Biol 1999; 82: 191-194.
23. Haas J. High dose IVIG in the post partum period for prevention of exacerbations in MS. Mult Scler 2000; 6 (Suppl 2): S18-S20; discussion S33.
24. Visser LH, Beekman R, Tijssen CC, Uitdehaag BM, Lee ML, Movig KL et al. A randomized, double-blind, placebo-controlled pilot study of iv immune globulins in combination with iv methylprednisolone in the treatment of relapses in patients with MS. Mult Scler 2004; 10: 89-91.
25. Sorensen PS, Haas J, Sellebjerg F, Olsson T, Ravnborg M, the TARIMS Study Group. IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS. Neurology 2004; 63: 2028-2033.
26. Roed HG, Langkilde A, Sellebjerg FT, Lauritzen M, Bang P, Moerup A ef al. The effect of IVIG treatment on visual outcome after acute optic neuritis (ON): A double-blind, randomized, placebo-controlled trial. Neurology 2004; 62 (Suppl 5):A261.
27. Bieber AJ, Warrington A, Pease LR, Rodriguez M. Humoral autoimmunity as a mediator of CNS repair. Trends Neurosci 2001; 24 (11 Suppl): S39-S44.
28. van Engelen BG, Hommes OR, Pinckers A, Cruysberg JR, Barkhof F, Rodriguez M. Improved vision after intravenous immunoglobulin in stable demyelinating optic neuritis. Ann Neurol 1992;32: 834-835.
29. Noseworthy JH, O'Brien PC, Petterson TM, Weis J, Stevens L, Peterson WK et al. A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology 2001; 56: 1514-1522.
30. Noseworthy JH, O'Brien PC, Weinshenker BG, Wells JA, Petterson TM, Erickson BJ et al. IV immunoglobulin does not reverse established weakness in MS. A double-blind, placebo-controlled trial. Neurology 2000; 55: 1135-1143.
31. Stangel M, Boegner F, Klatt CH, Hofmeister C, Seyfert S. Placebo controlled pilot trial to study the remyelinating potential of intravenous immunoglobulins in multiple sclerosis. J Neurol Neurosurg Psychiatry 2000; 68: 89-92.
32. Stangel M, Gold R. Use of IV immunoglobulins in neurology. Evidence-based consensus. Nervenarzt 2004; 75: 801-816 (in German).
33. Kalanie H, Tabatabai SS. Combined immunoglobulin and azathioprine in multiple sclerosis. Eur Neurol 1998; 39: 178-181.